NEW YORK (GenomeWeb) — The Translational Genomics Research Institute and Northern Arizona University have been jointly awarded a US patent for an allele-specific, real-time PCR-based assay to detect H1N1 pandemic flu and resistance to antiviral treatments.
DxNA, a privately owned St. George, Utah-based molecular diagnostics firm, will acquire privately held Flagstaff, Ariz.-based Pathogene for an undisclosed amount under an agreement inked by the companies this week.
DxNA of St. George, Utah, has been awarded US Patent No. 7,993,910, "Methods and apparatus for amplification of DNA using sonic energy."
William Bickmore and Danvern Ray Roberts are named as inventors on the patent.
The vote of confidence is a stepping stone for the company to seek 510(k) approval for an H1N1 test on its platform; to tackle the point-of-care diagnostic market; and to further develop tests for other infectious diseases.